Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hypertension

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 78 articles: HTML format

Single Articles

February 2023
1. 
   Corrigendum to: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respi
   Eur Heart J. 2023 Feb 23:ehad005. doi: 10.1093.
   PubMed    
   
   
   
2. VOLPE M, Gallo G, Rubattu S
   Endocrine functions of the heart: from bench to bedside.
   Eur Heart J. 2023;44:643-655.
   PubMed     Abstract available
   
   
   
3. VISWANATHAN G, Rajagopal S
   De novo purine synthesis: a new target in pulmonary arterial hypertension?
   Eur Heart J. 2023 Feb 20:ehad078. doi: 10.1093.
   PubMed    
   
   
   
4. BARBATO E, Azizi M, Schmieder RE, Lauder L, et al
   Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
   Eur Heart J. 2023 Feb 15:ehad054. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. VOLPE M, Liuzzo G
   The 'cold case' of chlortalidone vs. hydrochlorothiazide in hypertension closed by the diuretic comparison project?
   Eur Heart J. 2023 Feb 14:ehad077. doi: 10.1093.
   PubMed    
   
   
   
6. ROSENKRANZ S, Delcroix M, Giannakoulas G, Hoeper MM, et al
   The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
   Eur Heart J. 2023 Feb 1:ehad018. doi: 10.1093.
   PubMed    
   
   
   January 2023
7. MA Q, Yang Q, Xu J, Sellers HG, et al
   Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models.
   Eur Heart J. 2023 Jan 31:ehad044. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2022
8. PETERS R, Xu Y, Fitzgerald O, Aung HL, et al
   Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis.
   Eur Heart J. 2022;43:4980-4990.
   PubMed     Abstract available
   
   
   
9. VOLPE M, Patrono C
   The promise of selective aldosterone synthase inhibition for the management of resistant hypertension.
   Eur Heart J. 2022 Dec 20:ehac754. doi: 10.1093.
   PubMed    
   
   
   
10. CREA F
    Physical exercise, inflammation, and hypertension: how to improve cardiovascular prevention.
    Eur Heart J. 2022;43:4763-4766.
    PubMed    
    
    
    
11. O'SULLIVAN JW, Ashley EA, Elliott PM
    Polygenic risk scores for the prediction of cardiometabolic disease.
    Eur Heart J. 2022 Dec 7:ehac648. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2022
12. HAXHA S, Halili A, Malmborg M, Pedersen-Bjergaard U, et al
    Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry.
    Eur Heart J. 2022 Nov 26:ehac662. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. LAUDER L, Mahfoud F, Azizi M, Bhatt DL, et al
    Hypertension management in patients with cardiovascular comorbidities.
    Eur Heart J. 2022 Nov 7. pii: 6808663. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. SCHUTTE AE
    The promise and pitfalls of novel cuffless blood pressure devices.
    Eur Heart J. 2022;43:4222-4223.
    PubMed    
    
    
    October 2022
15. CREA F
    Update on a silent killer: arterial hypertension.
    Eur Heart J. 2022;43:3595-3598.
    PubMed    
    
    
    
16. RIVASI G, Groppelli A, Brignole M, Soranna D, et al
    Association between hypotension during 24 h ambulatory blood pressure monitoring and reflex syncope: the SynABPM 1 study.
    Eur Heart J. 2022;43:3765-3776.
    PubMed     Abstract available
    
    
    September 2022
17. GERDTS E, Sudano I, Brouwers S, Borghi C, et al
    Sex differences in arterial hypertension.
    Eur Heart J. 2022 Sep 22. pii: 6711154. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. CREA F
    Hypertension in children, adolescents, and pregnant women: challenges and opportunities.
    Eur Heart J. 2022;43:3275-3278.
    PubMed    
    
    
    
19. WHELTON PK, Carey RM, Mancia G, Kreutz R, et al
    Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines.
    Eur Heart J. 2022;43:3302-3311.
    PubMed     Abstract available
    
    
    August 2022
20. HUMBERT M, Kovacs G, Hoeper MM, Badagliacca R, et al
    2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
    Eur Heart J. 2022 Aug 26. pii: 6673929. doi: 10.1093.
    PubMed    
    
    
    
21. WENZEL P
    Thromboinflammation in cardiovascular disease: lessons learned for the management of hypertension, heart failure, and aortic valve stenosis.
    Eur Heart J. 2022 Aug 18. pii: 6671020. doi: 10.1093.
    PubMed    
    
    
    
22. PANDEY AK, Bhatt DL, Cosentino F, Marx N, et al
    Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Eur Heart J. 2022;43:2931-2945.
    PubMed     Abstract available
    
    
    
23. UMEI TC, Kishino Y, Kawakami T, Fukuda K, et al
    Recurrent pulmonary thrombosis after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.
    Eur Heart J. 2022 Aug 8. pii: 6658235. doi: 10.1093.
    PubMed    
    
    
    
24. WOUDA RD, Boekholdt SM, Khaw KT, Wareham NJ, et al
    Sex-specific associations between potassium intake, blood pressure, and cardiovascular outcomes: the EPIC-Norfolk study.
    Eur Heart J. 2022;43:2867-2875.
    PubMed     Abstract available
    
    
    
25. JOSEPH P, Kutty VR, Mohan V, Kumar R, et al
    Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy.
    Eur Heart J. 2022;43:2831-2840.
    PubMed     Abstract available
    
    
    
26. LI S, Liu Z, Joseph P, Hu B, et al
    Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy.
    Eur Heart J. 2022;43:2852-2863.
    PubMed     Abstract available
    
    
    
27. PRESCOTT E
    Lessons from PURE on modifiable risk.
    Eur Heart J. 2022;43:2864-2866.
    PubMed    
    
    
    
28. LOPEZ-JARAMILLO P, Joseph P, Lopez-Lopez JP, Lanas F, et al
    Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy.
    Eur Heart J. 2022;43:2841-2851.
    PubMed     Abstract available
    
    
    
29. CAULDWELL M
    Understanding the implications of hypertensive disorders in pregnancy in women with heart disease.
    Eur Heart J. 2022 Aug 3. pii: 6653698. doi: 10.1093.
    PubMed    
    
    
    
30. DACHS TM, Duca F, Rettl R, Binder-Rodriguez C, et al
    Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
    Eur Heart J. 2022 Aug 1. pii: 6652608. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. BAUERSACHS J, Olsson KM
    Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?
    Eur Heart J. 2022 Aug 1. pii: 6652609. doi: 10.1093.
    PubMed    
    
    
    July 2022
32. DE SIMONE G, Mancusi C, Hanssen H, Genovesi S, et al
    Hypertension in children and adolescents.
    Eur Heart J. 2022 Jul 27. pii: 6633855. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. TADIC M, Cuspidi C, Marwick TH
    Phenotyping the hypertensive heart.
    Eur Heart J. 2022 Jul 23. pii: 6648534. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. VERGALLO R, Volpe M
    Long lasting effects of renal denervation: lights and shadows of the SPYRAL HTN-ON MED 3-year follow-up.
    Eur Heart J. 2022;43:2655-2656.
    PubMed    
    
    
    
35. OMOTE K, Sorimachi H, Obokata M, Reddy YNV, et al
    Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.
    Eur Heart J. 2022 Jul 7. pii: 6633254. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. HOEPER MM, Rosenkranz S
    Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?
    Eur Heart J. 2022 Jul 7. pii: 6633248. doi: 10.1093.
    PubMed    
    
    
    June 2022
37. RAMLAKHAN KP, Malhame I, Marelli A, Rutz T, et al
    Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry.
    Eur Heart J. 2022 Jun 21. pii: 6612238. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2022
38. LUCAS-HERALD AK, Montezano AC, Alves-Lopes R, Haddow L, et al
    Vascular dysfunction and increased cardiovascular risk in hypospadias.
    Eur Heart J. 2022;43:1832-1845.
    PubMed     Abstract available
    
    
    
39. GALIUTO L, Volpe M
    Treatment of mild hypertension improves pregnancy outcomes.
    Eur Heart J. 2022 May 13. pii: 6585107. doi: 10.1093.
    PubMed    
    
    
    
40. SCHUTTE AE, Neal B
    The sodium hidden in medication: a tough pill to swallow.
    Eur Heart J. 2022;43:1756-1758.
    PubMed    
    
    
    April 2022
41. VALERIO L, Mavromanoli AC, Barco S, Abele C, et al
    Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study.
    Eur Heart J. 2022 Apr 28. pii: 6575686. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. OJJI D, Aifah A, Dulli L, Iwelunmor J, et al
    Early stakeholder engagement lessons from managing hypertension among people living with human-immunodeficiency virus: an integrated model (MAP-IT).
    Eur Heart J. 2022 Apr 20. pii: 6571044. doi: 10.1093.
    PubMed    
    
    
    March 2022
43. VOLPE M, Patrono C
    Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetes.
    Eur Heart J. 2022;43:1189-1190.
    PubMed    
    
    
    February 2022
44. ZENG C, Rosenberg L, Li X, Djousse L, et al
    Sodium-containing acetaminophen and cardiovascular outcomes in individuals with and without hypertension.
    Eur Heart J. 2022 Feb 24. pii: 6535634. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. RAM CVS
    Renal denervation therapy for hypertension: all that glitters is not gold.
    Eur Heart J. 2022 Feb 15. pii: 6529363. doi: 10.1093.
    PubMed    
    
    
    
46. VOLPE M, Patrono C
    Age-independent benefits of blood pressure lowering: are they applicable to all patients?
    Eur Heart J. 2022;43:448-449.
    PubMed    
    
    
    
47. MESSERLI FH, Siontis GCM, Bavishi C, Messerli AW, et al
    Importance of pulse pressure at low systolic blood pressure.
    Eur Heart J. 2022;43:540.
    PubMed    
    
    
    
48. SPENCE JD, Muller LO, Blanco PJ
    How to identify which patients should not have a systolic blood pressure target of <120 mmHg.
    Eur Heart J. 2022;43:538-539.
    PubMed    
    
    
    
49. CORRAO G, Mancia G
    Research strategies in treatment of hypertension: value of retrospective real-life data.
    Eur Heart J. 2022 Feb 3. pii: 6520830. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
50. VOLPE M, Patrono C
    Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?
    Eur Heart J. 2021;42:4885-4886.
    PubMed    
    
    
    
51. VOLPE M, Patrono C
    Another STEP towards tighter control of blood pressure in the elderly.
    Eur Heart J. 2021;42:4715-4716.
    PubMed    
    
    
    October 2021
52. MIHAILIDOU AS, Gulati M
    Impact of hypertensive disorders of pregnancy: lessons from CONCEPTION.
    Eur Heart J. 2021 Oct 18. pii: 6399973. doi: 10.1093.
    PubMed    
    
    
    
53. BOUCHERON P, Lailler G, Moutengou E, Regnault N, et al
    Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study.
    Eur Heart J. 2021 Oct 13. pii: 6395270. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
54. RUILOPE LM, Valenzuela PL, Lucia A
    Digital therapeutics and lifestyle: the start of a new era in the management of arterial hypertension?
    Eur Heart J. 2021 Sep 27. pii: 6377082. doi: 10.1093.
    PubMed    
    
    
    
55. CREA F
    The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Eur Heart J. 2021;42:3581-3585.
    PubMed    
    
    
    
56. FUKUMOTO Y
    Takayasu arteritis-associated pulmonary hypertension.
    Eur Heart J. 2021 Sep 20. pii: 6372800. doi: 10.1093.
    PubMed    
    
    
    
57. LINZ D, Gawalko M, Sanders P, Penders J, et al
    Does gut microbiota affect atrial rhythm? Causalities and speculations.
    Eur Heart J. 2021;42:3521-3525.
    PubMed     Abstract available
    
    
    
58. BAYES-GENIS A, Diez J
    Transition to heart failure in hypertension: going to the heart of the matter.
    Eur Heart J. 2021 Sep 13. pii: 6369562. doi: 10.1093.
    PubMed    
    
    
    
59. JIANG X, Zhu YJ, Zhou YP, Peng FH, et al
    Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide study.
    Eur Heart J. 2021 Sep 10. pii: 6368314. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. BROWN JM, Zhou W, Weber B, Divakaran S, et al
    Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease.
    Eur Heart J. 2021 Sep 7. pii: 6365821. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. MESSERLI FH, Bavishi C, Messerli AW, Siontis GCM, et al
    Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study.
    Eur Heart J. 2021 Sep 4. pii: 6364086. doi: 10.1093.
    PubMed    
    
    
    August 2021
62. KARIO K, Nomura A, Harada N, Okura A, et al
    Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial.
    Eur Heart J. 2021 Aug 29. pii: 6358480. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. VOLPE M, Gallo G
    Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
    Eur Heart J. 2021 Aug 15. pii: 6352588. doi: 10.1093.
    PubMed    
    
    
    
64. JACKSON AM, Jhund PS, Anand IS, Dungen HD, et al
    Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Eur Heart J. 2021 Aug 15. pii: 6352587. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
65. VOLPE M, Patrono C
    The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile.
    Eur Heart J. 2021;42:2814-2815.
    PubMed    
    
    
    June 2021
66. VOLPE M, Patrono C
    A SPRINT towards tighter control of blood pressure in hypertension.
    Eur Heart J. 2021 Jun 25. pii: 6309731. doi: 10.1093.
    PubMed    
    
    
    
67. HE FJ, Campbell NRC, Woodward M, MacGregor GA, et al
    Salt reduction to prevent hypertension: the reasons of the controversy.
    Eur Heart J. 2021 Jun 12. pii: 6297147. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. MESSERLI FH, Brguljan J, Rexhaj E, Sever P, et al
    Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit.
    Eur Heart J. 2021;42:2052-2059.
    PubMed    
    
    
    
69. YAN Y, Mu J
    Salt intake paradox: the estimation method matters.
    Eur Heart J. 2021;42:2133.
    PubMed    
    
    
    May 2021
70. LANDMESSER U, Lehmann I, Eils R
    Hyperinflammation as underlying mechanism predisposing patients with cardiovascular diseases for severe COVID-19.
    Eur Heart J. 2021;42:1720-1721.
    PubMed    
    
    
    April 2021
71. 
    Erratum to: A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment.
    Eur Heart J. 2021 Apr 13. pii: 6224359. doi: 10.1093.
    PubMed    
    
    
    March 2021
72. VAN DIEPEN S, Armstrong PW
    Learning whether to subtract beta-blockers: it's about time.
    Eur Heart J. 2021;42:915-918.
    PubMed     Abstract available
    
    
    February 2021
73. ESTRUCH R, Ruilope LM, Cosentino F
    The year in cardiovascular medicine 2020: epidemiology and prevention.
    Eur Heart J. 2021;42:813-821.
    PubMed    
    
    
    
74. WARTOLOWSKA KA, Webb AJS
    Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study.
    Eur Heart J. 2021;42:750-757.
    PubMed     Abstract available
    
    
    November 2020
75. LIEW CH, McEvoy JW
    The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.
    Eur Heart J. 2020;41:4284-4285.
    PubMed    
    
    
    
76. VOLPE M, Patrono C
    Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data.
    Eur Heart J. 2020;41:3986-3987.
    PubMed    
    
    
    March 2020
77. BOHM M, Ferreira JP, Mahfoud F, Duarte K, et al
    Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial.
    Eur Heart J. 2020 Mar 2. pii: 5771273. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2019
78. SHARASHOVA E, Wilsgaard T, Ball J, Morseth B, et al
    Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromso Study.
    Eur Heart J. 2019 May 3. pii: 5485289. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: